Back to Blog
Blueprint medicines6/12/2023 ![]() Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.įor a complete picture of BLU-451’s drug-specific PTSR and LoA scores, buy the report here. The company utilizes its discover which combines bioinformatics and drug design capabilities to develop its medicines. The more important of these is AYVAKIT/AYVAKYT, a kinase. The company has two products on the market already. Blueprint Medicines is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors and avapritinib to treat advanced systemic mastocytosis. Blueprint Medicines is just starting to move into the commercialization phase. With a focus on genomically defined cancers, rare diseases and cancer. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) against non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. Blueprint Medicines is a precision therapy company striving to improve human health. It is administered through oral route.īlueprint Medicines, formerly Hoyle Pharmaceuticals, is precision therapy company that inventing medicines for people with cancer and blood disorders. moving multiple investigational medicines through clinical development for patients with a broad range of. Preclinically, BLU-222 showed significant antitumor activity in a CCNE1-amplified ovarian cancer model, and BLU-222 in combination with standard of care agents led to sustained tumor regression even after treatment cessation.BLU-451 (LNG-451) under development for the treatment of non-small cell lung cancer. It acts by targeting epidermal growth factor receptor (EGFR) with Exon 20 insertions. In subsets of patients with ovarian cancer and other tumor types, aberrant CCNE1 hyperactivates CDK2, resulting in cell cycle dysregulation and tumor growth. However, prior drug discovery efforts targeting CDK2 have been hindered by challenges in achieving selectivity over other CDK family members associated with toxicity.ĬDK2 is believed to play an important role in tumor proliferation for patients with HR-positive, HER2-negative metastatic breast cancer. CDK2 and CCNE1 are central to regulating the cell cycle, which is involved in the process of cell growth and division. View Blueprint Medicines location in 45 Sidney St, Cambridge, Massachusetts, 02139, United States, revenue, industry and description. View clinical trials of avapritinib.īLU-222 is a potent and selective CDK2 inhibitor for the treatment of patients with CDK2-vulnerable cancers, including hormone receptor (HR)-positive, HER2-negative breast cancer and CCNE1 aberrant tumors. ![]() Food and Drug Administration (FDA) for the treatment of moderate to severe indolent SM.īlueprint Medicines is developing avapritinib as a potential treatment for a broad population of patients with SM globally, including advanced and non-advanced SM. That’s why we offer a range of personalized services to help you get onand stay onyour prescribed treatment. Call us today 1-888-BLUPRNT (1-88) Every person is unique. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. This is YourBlueprint ® We offer personalized services right from the start of your prescribed Blueprint Medicines therapy. – A minority of patients have advanced SM in addition to mast cell activation symptoms, it is associated with organ damage due to mast cell infiltration and poor overall survival.Īvapritinib has received breakthrough therapy designation from the U.S. Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. – The vast majority of those affected have non-advanced (indolent or smoldering) SM, with debilitating symptoms that lead to a profound, negative impact on quality of life. ![]() SM comprises a disease spectrum ranging from indolent SM, which is predominantly characterized by severe constitutional symptoms caused by mast cell degranulation and mediator release, to advanced SM, which is characterized by organ dysfunction and reduced survival due to mast cell infiltration. Systemic mastocytosis (SM) is a rare disease that results from the abnormal proliferation of mast cells across all forms of SM, the KIT D816V mutation is the primary driver of disease.
0 Comments
Read More
Leave a Reply. |